Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

June 6, 2022

Study Completion Date

April 17, 2023

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes

Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.

BIOLOGICAL

ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes

Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.

Trial Locations (1)

1105AZ

Amsterdam University Medical Centers, location AMC, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT03961438 - Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine | Biotech Hunter | Biotech Hunter